[go: up one dir, main page]

TR200200420T2 - Aşı - Google Patents

Aşı

Info

Publication number
TR200200420T2
TR200200420T2 TR2002/00420T TR200200420T TR200200420T2 TR 200200420 T2 TR200200420 T2 TR 200200420T2 TR 2002/00420 T TR2002/00420 T TR 2002/00420T TR 200200420 T TR200200420 T TR 200200420T TR 200200420 T2 TR200200420 T2 TR 200200420T2
Authority
TR
Turkey
Prior art keywords
rotavirus
provides
single variant
vaccine
tongue
Prior art date
Application number
TR2002/00420T
Other languages
English (en)
Inventor
Desiree Alberte Colau Brigitte
Denamur Francoise
Knott Isabelle
Polisczak Annick
Thiry Georges
Vande Velde Vincent
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919468.0A external-priority patent/GB9919468D0/en
Priority claimed from GBGB9927336.9A external-priority patent/GB9927336D0/en
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR200200420T2 publication Critical patent/TR200200420T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Bu bulus VP4 ve VP7 olarak gösterilen ana viral proteinlerinden en az birisini sifreleyen nükleotik sekans tarafindan tanimlanan tek varyant veya tam tek varyant ihtiva eden zayiflatilmis rotavirüs popülasyonu saglar.Bu bulus özel olarak P43 olarak gösterilen bir rotavirüs popülasyonu saglar. Bu bulus daha ileriye giderek dilin üzerine konuldugunda hemen erimesi için çabuk çözünen tablet formunda rotavirüs asisi için yeni bir formülasyon saglar.
TR2002/00420T 1999-08-17 2000-08-15 Aşı TR200200420T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine
GBGB9927336.9A GB9927336D0 (en) 1999-11-18 1999-11-18 Vaccine

Publications (1)

Publication Number Publication Date
TR200200420T2 true TR200200420T2 (tr) 2002-05-21

Family

ID=26315853

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00420T TR200200420T2 (tr) 1999-08-17 2000-08-15 Aşı

Country Status (42)

Country Link
US (4) US7285280B1 (tr)
EP (1) EP1212084B1 (tr)
JP (3) JP2003507040A (tr)
KR (1) KR100695599B1 (tr)
CN (1) CN100379451C (tr)
AP (1) AP1768A (tr)
AR (1) AR029643A1 (tr)
AT (1) ATE327765T1 (tr)
AU (1) AU767885B2 (tr)
BG (1) BG65314B1 (tr)
BR (1) BRPI0013357B8 (tr)
CA (1) CA2379196C (tr)
CO (1) CO5580165A1 (tr)
CY (2) CY1106103T1 (tr)
CZ (1) CZ302173B6 (tr)
DE (2) DE60028390T2 (tr)
DK (1) DK1212084T3 (tr)
DZ (1) DZ3219A1 (tr)
EA (1) EA005952B1 (tr)
ES (1) ES2260046T3 (tr)
FR (1) FR06C0018I2 (tr)
HK (1) HK1046860B (tr)
HU (2) HU228975B1 (tr)
IL (3) IL147926A0 (tr)
LU (1) LU91251I2 (tr)
MA (1) MA25489A1 (tr)
MX (1) MXPA02001648A (tr)
MY (1) MY133158A (tr)
NL (1) NL300233I2 (tr)
NO (2) NO328112B1 (tr)
NZ (1) NZ517131A (tr)
OA (1) OA12312A (tr)
PE (1) PE20010487A1 (tr)
PL (1) PL205550B1 (tr)
PT (1) PT1212084E (tr)
SI (1) SI1212084T1 (tr)
SK (1) SK287261B6 (tr)
TR (1) TR200200420T2 (tr)
TW (1) TWI283270B (tr)
UA (1) UA77388C2 (tr)
UY (1) UY26297A1 (tr)
WO (1) WO2001012797A2 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028390T2 (de) * 1999-08-17 2006-11-02 Glaxosmithkline Biologicals S.A. Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
AU2004268375B2 (en) 2003-09-02 2010-01-28 Glaxosmithkline Biologicals S.A. Vaccine
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CA2619751C (en) * 2005-08-17 2016-07-05 Glaxosmithkline Biologicals S.A. Vaccine
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
KR101051986B1 (ko) * 2006-09-28 2011-07-26 중앙대학교 산학협력단 인간로타바이러스 및 이를 이용한 백신 조성물
EP2099485B1 (en) 2006-11-03 2018-03-21 AlphaVax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2010132561A2 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
RU2553331C2 (ru) 2009-07-13 2015-06-10 Бхарат Байотек Интернэшнл Лимитед Композиция, применимая в качестве ротавирусной вакцины, и способ ее получения
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
WO2013160913A1 (en) 2012-04-23 2013-10-31 Bharat Biotech International Limited Rotavirus vaccine compositions and process for preparing the same
NZ631348A (en) * 2012-08-27 2017-02-24 Murdoch Childrens Res Inst Modified human rotaviruses and uses therefor
SI3299384T1 (sl) * 2015-05-21 2022-05-31 Xiamen University Skrajšan protein rotavirusa VP4 in njegova uporaba
EP3359651A1 (en) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Human rota virus g9p[6]strain and use as a vaccine
EP3373965A1 (en) * 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
CA3006069A1 (en) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Thermally stable rotavirus vaccine formulations and methods of use thereof
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110856493B (zh) * 2018-08-20 2022-02-25 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用
WO2024242174A1 (ja) * 2023-05-24 2024-11-28 国立大学法人大阪大学 一回感染性ロタウイルスおよびその利用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927323B2 (ja) * 1976-10-12 1984-07-05 花王株式会社 歯みがき組成物
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
EP0152295B1 (en) * 1984-02-09 1991-03-20 Royal Children's Hospital Research Foundation Live attenuated human rotavirus vaccine and preparation thereof
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
BR9106982A (pt) * 1990-11-16 1993-08-31 Gamble James N Med Inst Vacine e processo para fornecer protecao umunologica contra doenca de rotavirus em seres humanos,rotavirus isolado,cepa de rotavirus isolado,rotavirus reagrupado em intergenogrupo humano isolado,e processo de aumentar titulos de anticorpo neutralizante
US5471385A (en) * 1992-05-21 1995-11-28 Tsubakimoto Chain Co. Routeless guiding method for moving body
US5773009A (en) * 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
AU3125795A (en) * 1994-07-11 1996-02-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Attenuated human rotavirus vaccine
ATE377428T1 (de) * 1996-09-26 2007-11-15 Merck & Co Inc Rotavirus-impfstoff
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DE60028390T2 (de) * 1999-08-17 2006-11-02 Glaxosmithkline Biologicals S.A. Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff

Also Published As

Publication number Publication date
NL300233I1 (nl) 2006-09-01
CZ302173B6 (cs) 2010-11-24
DE60028390D1 (de) 2006-07-06
BRPI0013357B1 (pt) 2016-08-02
BG106417A (en) 2003-04-30
SK287261B6 (sk) 2010-04-07
SK2432002A3 (en) 2002-09-10
AU6996100A (en) 2001-03-13
IL147926A0 (en) 2002-08-14
HK1046860A1 (en) 2003-01-30
US7790179B2 (en) 2010-09-07
US20080057082A1 (en) 2008-03-06
AP2002002424A0 (en) 2002-03-31
CY2006004I1 (el) 2009-11-04
DE60028390T2 (de) 2006-11-02
EA005952B1 (ru) 2005-08-25
FR06C0018I2 (fr) 2007-04-27
CA2379196A1 (en) 2001-02-22
NO2010011I2 (no) 2015-02-02
HK1046860B (en) 2006-10-06
BG65314B1 (bg) 2008-01-31
CY1106103T1 (el) 2010-07-28
WO2001012797A2 (en) 2001-02-22
AR029643A1 (es) 2003-07-10
CN100379451C (zh) 2008-04-09
AP1768A (en) 2007-08-16
DZ3219A1 (fr) 2001-02-22
PL354135A1 (en) 2003-12-29
IL188686A0 (en) 2008-04-13
DK1212084T3 (da) 2006-07-10
NO328112B1 (no) 2009-12-07
EP1212084B1 (en) 2006-05-31
JP2003507040A (ja) 2003-02-25
BRPI0013357B8 (pt) 2021-05-25
KR20020092344A (ko) 2002-12-11
US7790180B2 (en) 2010-09-07
HU228975B1 (en) 2013-07-29
NZ517131A (en) 2003-07-25
OA12312A (en) 2006-05-12
UA77388C2 (uk) 2006-12-15
MY133158A (en) 2007-10-31
BR0013357A (pt) 2002-04-30
MXPA02001648A (es) 2002-08-06
US7285280B1 (en) 2007-10-23
FR06C0018I1 (tr) 2006-07-21
HUP0203335A1 (hu) 2003-02-28
JP5474720B2 (ja) 2014-04-16
PL205550B1 (pl) 2010-04-30
TWI283270B (en) 2007-07-01
NL300233I2 (nl) 2006-10-02
NO20020763L (no) 2002-04-16
ATE327765T1 (de) 2006-06-15
HUP0203335A3 (en) 2004-07-28
PT1212084E (pt) 2006-07-31
CA2379196C (en) 2015-05-26
CZ2002522A3 (cs) 2002-05-15
JP2007319164A (ja) 2007-12-13
CO5580165A1 (es) 2005-11-30
DE122006000026I1 (de) 2006-10-12
SI1212084T1 (sl) 2006-08-31
WO2001012797A3 (en) 2001-08-02
CN1379683A (zh) 2002-11-13
JP2011045374A (ja) 2011-03-10
CY2006004I2 (el) 2009-11-04
AU767885B2 (en) 2003-11-27
MA25489A1 (fr) 2002-07-01
NO2010011I1 (no) 2010-06-07
EP1212084A2 (en) 2002-06-12
IL147926A (en) 2008-03-20
US20090130145A1 (en) 2009-05-21
ES2260046T3 (es) 2006-11-01
EA200200142A1 (ru) 2002-08-29
KR100695599B1 (ko) 2007-03-14
LU91251I9 (tr) 2018-12-31
UY26297A1 (es) 2001-03-16
NO20020763D0 (no) 2002-02-15
PE20010487A1 (es) 2001-06-23
US20080063662A1 (en) 2008-03-13
HUS1300072I1 (hu) 2019-11-28
LU91251I2 (fr) 2006-08-14

Similar Documents

Publication Publication Date Title
TR200200420T2 (tr) Aşı
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
CY1116491T1 (el) Εμβολιο εναντι του αφθωδους πυρετου
ES2153223T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
NO20020348D0 (no) Peptid acceptor ligeringsmetoder
CY1107448T1 (el) Συνθεσεις και εμβολια που περιεχουν αντιγονο(-α) cryptosporidium parvum και αλλου εντερικου παθογονου
TR200200768T2 (tr) Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri
DK1328543T3 (da) Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
DK1526175T4 (da) Coronavirus, nukleinsyre, protein og fremgangsmåder til generering af vaccine, lægemidler og diagnostik
IL153464A0 (en) A controlled release oral drug dosage form
ES2139086T3 (es) El transposon tn5401 del bacillus thuringiensis y su uso en un sistema de recombinacion especifica de sitio para el desarrollo de cepas del bacillus thuringiensis.
DK1138333T3 (da) Medicinske præparater til oral anvendelse
ES2069742T3 (es) Proteina de la capsida del calicivirus felino y secuencia nucleotida.
Wilson Tile-stamps of Philippianus in Late Roman Sicily: a Talking signum or Evidence for Horse-raising?
ATE248601T1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
ATE234628T1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
AR015586A1 (es) Composicion farmaceutica de residencia gastrica.
CY1109976T1 (el) Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου
ES2122973T3 (es) Vacuna de recombinante de rotavirus.
Chong The first generation of earthquake-triggered landslide probability map of China: Errata
TENUTA et al. Fluoride release of four restorative glass-ionomer cements
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
TR200000054A2 (tr) Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
Judis Show and tell.